Recruiting OBSERVATIONAL NCT00414115

National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

Canadian Pharmacogenomics Network for Drug Safety

Sponsor: British Columbia Clinical Genomics Network

Updated 3 times since 2024 Last updated: Mar 24, 2025 Started: Aug 31, 2005 Primary completion: Mar 31, 2029 Completion: Mar 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Adverse Drug Reaction (ADR), this trial is actively recruiting participants. The trial is conducted by British Columbia Clinical Genomics Network and has accumulated 3 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Jan 2026 — Present [monthly]

Recruiting
Apr 2025 — Jan 2026 [monthly]

Recruiting
Sep 2024 — Apr 2025 [monthly]

Recruiting

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

British Columbia Clinical Genomics Network
Canada Foundation for Innovation
Canada Gene Cure
Canadian Institutes of Health Research (CIHR)
Canadian Society of Clinical Pharmacology
Child and Family Research Institute
Eli Lilly and Company
Genome British Columbia
Genome Canada
Health Canada
Merck Sharp & Dohme LLC
Pfizer
Provincial Health Services Authority British Columbia
University of British Columbia
Western University, Canada

Data source: University of British Columbia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada